I-Mab logo

I-MabNASDAQ: IMAB

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

17 January 2020

Next earnings report:

14 March 2025

Last dividends:

N/A

Next dividends:

N/A
$89.21 M
-98%vs. 3y high
42%vs. sector
-39%vs. 3y high
7%vs. sector
-94%vs. 3y high
25%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 01 Nov 2024 21:50:02 GMT
$1.15+$0.08(+7.48%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

IMAB Latest News

I-Mab to Release Q3 2024 Financial Results on November 14, 2024
prnewswire.com31 October 2024 Sentiment: POSITIVE

ROCKVILLE, Md. , Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time.

I-Mab to Participate at the Truist Securities BioPharma Symposium
prnewswire.com28 October 2024 Sentiment: POSITIVE

ROCKVILLE, Md. , Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024.

IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade
zacks.com09 October 2024 Sentiment: POSITIVE

IMab (IMAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
prnewswire.com16 September 2024 Sentiment: POSITIVE

Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levels The recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; givastomig was well tolerated up to the highest study doses A Phase 1b study, evaluating givastomig in combination with standard-of-care treatment (nivolumab + chemotherapy (FOLFOX)) in front-line gastric cancer patients, is ongoing ROCKVILLE, Md. , Sept. 16, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced a poster presentation highlighting encouraging top-line results from its ongoing Phase 1 clinical study (NCT04900818) of givastomig, a novel first-in-class/ Claudin18.2 (CLDN18.2) and 4-1BB bispecific antibody immunostimulant, in patients with advanced cancers, especially gastric cancers (including gastroesophageal carcinoma, or GEC) at the European Society for Medical Oncology (ESMO) Congress 2024, taking place in Barcelona, Spain.

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates
prnewswire.com28 August 2024 Sentiment: POSITIVE

Completed divestiture of China operations Uliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody) Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific) Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific) Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into 2027 I-Mab will hold a conference call and webcast today, August 28 th, at 8:00 AM ET ROCKVILLE, Md., Aug. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and six months ended June 30, 2024, and highlighted recent pipeline progress and business updates.

I-Mab to Release 1H 2024 Financial Results on August 28, 2024
prnewswire.com14 August 2024 Sentiment: POSITIVE

Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.

I-Mab Announces Leadership Transitions
prnewswire.com15 July 2024 Sentiment: POSITIVE

ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr.

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
globenewswire.com23 May 2024 Sentiment: POSITIVE

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that Gerald Falchook, MD, and the team at I-Mab's partner for ragistomig (or “ABL503”), ABL Bio (KOSDAQ: 298380), will present a poster related to Phase 1 data for ragistomig at the 2024 American Society for Clinical Oncology Annual Meeting (“ASCO 2024”), taking place from May 31st to June 4th at the McCormick Place Convention Center in Chicago, IL.

I-Mab: Trading Below Net Cash With Multiple Upside Options
Seeking Alpha18 February 2024 Sentiment: POSITIVE

I-Mab Biopharma has signed an agreement to divest its assets and business operations in China, becoming a US-based biotech company. The divesting will provide I-Mab with a healthy balance sheet, over $400 million in cash, and the potential to receive up to $80 million in cash consideration from its divested China operation. I-Mab's core assets will consist of three global Immuno-Oncology programs, including uliledlimab, which has shown promising Phase 2 NSCLC clinical trial data.

Biotech firm I-Mab to divest China operations, shift focus to US
Reuters07 February 2024 Sentiment: POSITIVE

I-Mab said on Wednesday it has agreed to divest its operations and assets in China as part of its strategy to become a U.S.-focused biotech firm, sending the company's shares up nearly 11% in premarket trading.

What type of business is I-Mab?

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

What sector is I-Mab in?

I-Mab is in the Healthcare sector

What industry is I-Mab in?

I-Mab is in the Biotechnology industry

What country is I-Mab from?

I-Mab is headquartered in United States

When did I-Mab go public?

I-Mab initial public offering (IPO) was on 17 January 2020

What is I-Mab website?

https://ir.i-mabbiopharma.com

Is I-Mab in the S&P 500?

No, I-Mab is not included in the S&P 500 index

Is I-Mab in the NASDAQ 100?

No, I-Mab is not included in the NASDAQ 100 index

Is I-Mab in the Dow Jones?

No, I-Mab is not included in the Dow Jones index

When was I-Mab the previous earnings report?

No data

When does I-Mab earnings report?

The next expected earnings date for I-Mab is 14 March 2025